Cordis, a unit of J&J, received European CE Mark approval for its RENLANE renal denervation system for treatment of blood pressure in patients for whom traditional therapy is not effective. The catheter is powered by an external multi-channel RF generator and features five irrigated electrodes through which energy is delivered to denervate renal arteries that are participants in controlling blood pressure.
The company already announced initial procedures using the device at the University of Cologne Hospital in Germany to treat patients with a systolic blood pressure over 160 mm Hg. The patients were discharged after a day at the hospital and we’re very curious, considering Medtronic’s recent failure with their own renal denervation system, to see what the long term impact of this therapy is on patients.
Press release: Cordis Corporation Receives CE Mark for RENLANE™ Renal Denervation System to Treat Resistant Hypertension…